Cas12a/crRNA recognition initiated self-priming mediated chain extension for colorimetric cell-free DNA (cfDNA) analysis

被引:0
|
作者
Li, Ming [1 ]
Zheng, Ting [1 ]
Zhu, Jiaqi [1 ]
Zhang, Hu [1 ]
Fan, Lijuan [1 ]
机构
[1] Wuhan Univ Sci & Technol, Dept Lab Med, Tianyou Hosp, 9 Tujialing,Dingziqiao Rd, Wuhan 430064, Hubei, Peoples R China
关键词
TARGET; BRCA1;
D O I
10.1039/d4an01432d
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Cell-free DNA (cfDNA) has attracted increasing attention as a promising biomarker in liquid biopsy due to its crucial role in disease diagnosis. However, previous cfDNA detection methods are commonly based on the development of target-specific primers and integrated signal amplification strategies, which may induce false-positive results. This paper presents a sensitive yet accurate method for cfDNA detection that combines phosphorothioated-terminal hairpin creation with a self-priming extension process. This approach initiates a self-priming mediated chain extension-based signal cycle following the trans-cleavage of H0@MBs when the CRISPR-Cas12a complex is activated by target cfDNA, resulting in the production of a substantial quantity of pyrophosphate. A pyrophosphate sensing probe (pp probe) was utilized, facilitating both high-efficiency and stable colorimetric signaling. This innovative technique for colorimetric detection of target cfDNA demonstrated exceptional sensitivity with a low limit of detection of 1.04 fM and greatly enhanced selectivity, with the complete detection process taking around 60 min. In addition, this technique is capable of detecting cfDNA from the culture medium of HEK293 cells, indicating its clinical application potential. Compared with the previous CRISPR-Cas system-based cfDNA method that necessitates an amplification step before detection, Cas12a was directly used to identify a target sequence that can avoid false target amplification. This technique is simple, accurate, and rapid, engineered to identify cancer-associated cfDNA via a highly sensitive colorimetric change, which is expected to be beneficial for applications requiring point-of-care cancer detection.
引用
收藏
页码:258 / 263
页数:6
相关论文
共 7 条
  • [1] CRISPR-Cas12a based target recognition initiated duplex-specific nuclease enhanced fluorescence and colorimetric analysis of cell-free DNA (cfDNA)
    Zhao, Chenglong
    Yang, Zhipeng
    Hu, Tengfei
    Liu, Jingwei
    Zhao, Yibo
    Leng, Dongming
    Yang, Kun
    An, Gang
    TALANTA, 2024, 271
  • [2] Reliable and precise lipoprotein detection based on a self-priming hairpin-triggered Cas12a/crRNA based signaling strategy
    Liu, Xiaoya
    Peng, Hai
    Gong, Lisha
    Zhang, Hong
    Zhao, Chenglong
    Lai, Weiju
    An, Gang
    Zhao, Xianxian
    ANALYST, 2024, 150 (01) : 46 - 54
  • [3] Adsorption-Free Self-Priming Direct Digital Dual-crRNA CRISPR/ Cas12a-Assisted Chip for Ultrasensitive Detection of Pathogens
    Xia, Liping
    Yin, Juxin
    Zhuang, Jianjian
    Yin, Weihong
    Zou, Zheyu
    Mu, Ying
    ANALYTICAL CHEMISTRY, 2023, 95 (10) : 4744 - 4752
  • [4] Chain extension-mediated colorimetric and sensitive detection of osteosarcoma-related miRNA based on CHA-cooperated self-priming
    Liu, Wen
    Yang, Yunfei
    Xiao, Gongyi
    Tang, Chun
    Deng, Zhongliang
    JOURNAL OF ANALYTICAL SCIENCE AND TECHNOLOGY, 2024, 15 (01)
  • [5] CRISPR-Cas12a recognition mediated self-priming assisted Primer Exchange Reaction (CspPER) for sensitive methicillin-resistant Staphylococcus aureus (MRSA) detection
    Wang, Xiaolan
    Jiang, Ying
    MICROCHEMICAL JOURNAL, 2025, 208
  • [6] CRISPR-Directed In Vitro Gene Editing of Plasmid DNA Catalyzed by Cpf1 (Cas12a) Nuclease and a Mammalian Cell-Free Extract
    Sansbury, Brett M.
    Wagner, Amanda M.
    Nitzan, Erez
    Tarcic, Gabi
    Kmiec, Eric B.
    CRISPR JOURNAL, 2018, 1 (02): : 191 - 202
  • [7] Diagnostic Value of Cross-priming Amplification Combined With CRISPR-Cas12b in Detecting Cell-free DNA in Tuberculous Pleural Effusion
    Peng, Lijun
    Fang, Tingting
    Dai, Lingshan
    Cai, Long
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (12):